Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,203.20
(
0.00%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
101.61
(
0.40%
)
Bitcoin
78,401.73
(
0.16%
)
News Focus
News Focus
Post# of 257441
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: caravon post# 188446

Wednesday, 03/11/2015 10:44:13 AM

Wednesday, March 11, 2015 10:44:13 AM

Post# of 257441

ABBV/ENTA—What if EDP-239 is superior to ABT-530? Then Enta has the COMBO (ABT-493 + EDP-239) superior to Abbv's Next-Gen. Enta becomes a very attractive acquisition candidates and Abbv knows it!

It doesn’t work that way; ABT-493 has been exclusively licensed to ABBV, so it can’t be used in one of ENTA’s wholly-owned HCV regimens.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today